Analyst Sean Laaman from Morgan Stanley maintained a Buy rating on Jazz Pharmaceuticals and decreased the price target to $165.00 from $166.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sean Laaman has given his Buy rating due to a combination of factors that suggest a positive outlook for Jazz Pharmaceuticals. Despite a 10% shortfall in net product sales for the first quarter, there is an anticipated recovery and growth in the second quarter, with expectations of stronger performance in the latter half of the year. This optimism is driven by factors such as an additional shipping week in the Oncology pipeline, improved performance for Rylaze due to updates in pediatric oncology protocols, and better seasonality in sleep revenues.
Furthermore, the company is expected to hit a crucial inflection point in the second half of the year, with significant clinical catalysts on the horizon, including the HERIZON-GEA-01 data and the dordaviprone PDUFA. The upcoming leadership transition, with Renee Gala taking over as CEO, also adds to the potential for positive change. Laaman’s projections for Oncology product revenues exceed Street estimates, reinforcing the Buy rating as the company positions itself for future growth.
In another report released on July 18, Wells Fargo also maintained a Buy rating on the stock with a $170.00 price target.